AbCellera To Release Top-Line Data From Phase 2 Trial Evaluating ABCL635 For Treatment Of Moderate-To-Severe Vasomotor Symptoms Due To Menopause On August 10

Management to host a conference call and live webcast at 4:30 a.m. PT / 7:30 a.m. ET

AbCellera (NASDAQ:ABCL) will release top-line data from its Phase 2 trial evaluating ABCL635 for the treatment of moderate-to-severe vasomotor symptoms (VMS) due to menopause before the market opens on Monday, August 10, 2026 and hold an investor conference call at 4:30 a.m. Pacific Time (7:30 a.m. Eastern Time) the same day.